Zum Seiteninhalt springen
A first step in the development of a new treatment for a disease is the identification of a biological target. In Academia planned publications demand a fast decision on whether and what should be patented at such an early stage. However, what can be patented around a biological target? What data is necessary to do so? What makes sense from an economical point of view? And what makes sense from the view-point of an Academic Institute? The planned panel discussion will address these questions. For more information about the program, please see poster on the right hand side.


Montag, 29. Februar 2016
15 bis 17 Uhr


MDC-C Dendrit II/III
Robert-Rössle-Str. 10
13125 Berlin


Bis 24. Februar per E-mail bei Frau Maxi Hiller (maxi.hiller@mdc-berlin.de).